肺癌冷冻消融联合局部免疫治疗现状与探索  

Status and exploration of cryoablation combined with local immunotherapy for lung cancer

作　　者：安军 AN Jun(Department of Cardiothoracic Surgery,the Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital,Meizhou 514700,China;Department of Cardiothoracic Surgery,the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,China)

机构地区：[1]中山大学附属第三医院粤东医院心胸外科,广东梅州514700 [2]中山大学附属第三医院心胸外科,广东广州510630

出　　处：《中国医学物理学杂志》2024年第11期1411-1414,共4页Chinese Journal of Medical Physics

基　　金：教育部产学合作协同育人项目(22087043260712);梅州市医学科研项目(2024C0302005)。

摘　　要：冷冻消融不仅可致肿瘤细胞坏死和凋亡,同时还可释放出大量肿瘤抗原,激活免疫细胞,诱导产生抗肿瘤免疫反应。免疫治疗已是非小细胞肺癌最为重要的治疗手段之一。本文主要从肺癌冷冻消融治疗、冷冻消融引发的免疫反应、冷冻消融联合全身免疫治疗、冷冻消融联合局部免疫治疗等方面进行概述,重点就肺癌冷冻消融联合局部免疫治疗的策略与方法及目前相关研究现状进行探讨。Cryoablation can not only cause necrosis and apoptosis of tumor cells,but also release a large number of tumor antigens,activate immune cells,and induce anti-tumor immune responses.Immunotherapy has become one of the most important treatments for non-small cell lung cancer.The study provides an overview about cryoablation for lung cancer,immune response induced by cryoablation,cryoablation combined with systemic immunotherapy,and cryoablation combined with local immunotherapy,focusing on the strategy and method of cryoablation combined with local immunotherapy for lung cancer and the current research status.

关 键 词：肺癌 冷冻消融 局部免疫治疗 免疫相关不良反应 

分 类 号：R319[医药卫生—基础医学] R734.2